key: cord-0793842-f2tvt8uq
authors: Richard, Vincent R.; Zahedi, René P.; Eintracht, Shaun; Borchers, Christoph H.
title: An LC-MRM assay for the quantification of metanephrines from dried blood spots for the diagnosis of pheochromocytomas and paragangliomas
date: 2020-07-09
journal: Anal Chim Acta
DOI: 10.1016/j.aca.2020.06.020
sha: ae7e9136d2141f225d63f4ac79a6a0274d79a26b
doc_id: 793842
cord_uid: f2tvt8uq

The quantitation of metanephrine (MN), normetanephrine (NMN), and 3-methoxytyramine (3MT) – referred to as metanephrines -- by LC-MS/MS is the gold-standard for screening for pheochromocytoma and paragangliomas (PPGLs), tumors of the adrenal gland and the peripheral nervous system. An assay for metanephrines from dried blood spots (DBSs) would be of high clinical utility as it simplifies sample collection, enables remote sampling, and could increase compliance with the clinical recommendation for supine sampling. Moreover, DBS sampling facilitates the measurement of blood-derived metanephrines in pediatric patients – where DBSs are well-established – in order to diagnose neuroblastomas. Here, we adapted an established derivatization-based LC-MRM-MS assay for plasma catecholamines, and optimized the sample extraction, LC, and MS parameters to produce a fast, sensitive, and robust method for the measurement of metanephrines from DBSs, including 3-methoxytyramine. The DBS samples were excised, derivatized with phenyl isothiocyanate (PITC) on-spot, extracted, and measured by LC-MRM-MS. To validate assay suitability and performance, we assessed the linearity, precision, accuracy, recovery, and matrix effects of the method, and determined the stability of metanephrines in DBSs under different storage conditions. Assay performance for NMN, MN, and 3MT was sufficient for quantitation from a single DBS within a linear range from 40 – 2000 pg/mL MN and NMN were stable in DBSs for 2 weeks, whereas 3MT was stable for one week regardless of storage temperature. Altogether, this work represents the first quantitative LC-MS/MS method for metanephrines from DBSs and provides a novel opportunity for the diagnosis of PPGLs and neuroblastomas in the future.

Pheochromocytomas and paragangliomas (PPGLs) are tumours arising from the adrenal 49 medulla or extra-adrenal ganglia which produce excessive amounts of catecholamines, 50 having potentially life-threatening effects on the cardiovascular system. Metanephrine (MN), 51 normetanephrine (NMN), and 3-methoxytyramine (3MT) are the o-methylated metabolic 52 products of the catecholamines norepinephrine, epinephrine, and dopamine, respectively, and 53 are referred to as metanephrines (MNs). Under proper sampling conditions, LC-MS based 54 determination of plasma MNs is the gold standard for first-line screening of these 55 neuroendocrine tumours [1] . Despite the proven efficacy of methods for determination of 56

MNs from urine or plasma, there exist considerable drawbacks with regard to sampling time, 57 storage, and cost. Urine measurements are made after 24-hour collection, which is both time-58 consuming and inconvenient for patients. In contrast, pediatric urine samples are typically 59 normalized to creatinine due to large inter-and intra-patient changes in urine concentration, 60 which requires an additional measurement. The current clinical guidelines for the sampling 61 of venous blood for the quantification of plasma MNs recommend rest in a supine position 62 for approximately 30 minutes [2], which is time consuming and hard to realize under typical 63 hospital test centre conditions. Another important consideration in favour of DBS sample 64 collection for the analysis of metanephrines is that DBS samples may actually be more stable 65 for short term storage than whole blood which is often stored at room temperature for 66 extended periods of time prior to centrifugation (for plasma or serum) and either analysis or 67 storage -which is known to lead to bias in the measurement of these analytes [3, 4] . 68

The analysis of a variety of metabolites from (DBS) has a number of advantages over the 69 analysis of other commonly analysed biofluids [5] [6] [7] [8] [9] . In the context of MNs, minimally 70 invasive DBS collection is a fast sampling technique that would be beneficial to the clinical 71 laboratory as it reduces patient discomfort and inconvenience, improves sample collection 72 concentrated at room temperature using a Labconco Centrivap, reconstituted in 20 µL of 121 water, and transferred to glass HPLC vial inserts. 122 123

Chromatographic separation of DBS extracts was conducted using an Agilent Zorbax Eclipse 126 Plus C18 column (2.1 x 150 mm, 1.8 µm 95Å particle size) and a 10-min binary gradient on a 127

Shimadzu Nexera XR UHPLC system. Mobile phase A was 0.1% aqueous formic acid and B 128 was acetonitrile with 0.1% formic acid. The flow rate was set to 400 µL/min. The gradient 129 began with a brief equilibration phase for 0.5 minutes at 5% B before increasing from 5 -130 40% B over 1 minute, then 40% to 50% B over 4 minutes, then immediately from 50% to 131 95% B which was held for 2 min before returning to 5% B, which was held for 3 minutes. 132

The injection volume was 20 µL, the column heater compartment was thermostatted at 50°C, 133 and the autosampler was refrigerated at 4°C. 134 135

Samples were analysed by MRM using a Sciex QTrap 6500+ mass spectrometer operated in 137 positive ion mode. The instrument was controlled using Analyst 1.6. Source parameters 138 were optimized as follows: capillary voltage of 5.5 kV, source temperature of 500°C, ion 139 source gases 1 and 2 were 60 and 50 respectively, collision gas was set to high, and the 140 curtain gas was set to 25. For MRM experiments, Q1 and Q3 were set to unit resolution. 141

Collision energies, declustering potentials, and cell exit potentials were optimized by direct 142 infusion of PITC-derivatized metanephrine reference standards (including MN, NMN, 3MT, 143

and their deuterium labelled analogs) using the manual tune interface in Analyst v1.7 (see 144 Table 1 ). From this acquired MS/MS data, we determined the best 156 candidate ion transitions, which were then further optimized as described above. Acquired MRM data was visualized, analysed, and reported using Skyline daily version 4.2.1 162 available at https://skyline.ms/ [12] . After importing the data, manually inspecting it for 163 correct peak assignment and integration in Skyline, and comparing the relative peak area 164 ratios of quantifier and qualifier transitions to verify the peak purity, the peak area ratios for 165 single quantifier-ion transitions were calculated, and the assay linearity was assessed using 166 linear regression with 1/x 2 regression weighting (the qualifier ion transitions are shown in 167 Precision was calculated as the % CV between all runs of the same concentration level (N=4 197 for intra-assay, N=12 for inter-assay precision), and was deemed to be acceptable if the % 198 CV was <15%. Inter-assay accuracy and precision were assessed over a minimum of three 

Carryover was assessed in triplicate by measuring matrix double blank samples immediately 230 after injecting the highest calibrator samples. Acceptable carryover required the total area of 231 the blanks to be less than 20% of the LLOQ peak area. 232

In order to develop a method for MNs from DBS, we initially used a relatively complex 235 sample preparation protocol entailing whole DBS excision, resolubilization of the DBS in 236 water, molecular weight cut-off filtration (MWCO), and solid phase extraction (Waters 237 HLB). Although this method met our performance criteria (linearity, precision, accuracy, 238 reproducibility, etc.) it suffered from several issues, the first of which was the length, complexity, and cost of the sample preparation itself. This was due to the multiple transfer 240 steps and the lengthy drying times, as well as the dependence on a relatively expensive means 241 of sample clean-up using MWCO filters and SPE cartridges or plates. The second problem 242 was the reliance on reversed-phase chromatography using pentafluorophenyl (PFP) and 243 biphenyl column phases, which, in our hands, showed poor robustness due to repeated issues 244 with deteriorating peak shape and progressive loss of compound retention. Third, despite the 245 relatively complex sample preparation, pronounced matrix effects were still observed with 246 this method (data not shown). To address these issues, we modified a method that had been 247 

Assay recovery and matrix effects are summarized in Table 2 . Recovery was modest for all 288 three metabolites, and matrix effects were observed for all three metabolites, but were highest 289 for NMN and 3MT (49.5%, and 45.6% respectively). Despite the modest recovery and 290 considerable matrix effects for all three metabolites, the assay achieved low to acceptable 291

CVs between independently-generated triplicates, indicating that the extraction is 292 reproducible. 293 294 

Due to the presence of endogenous MNs in human blood, and the apparent lack of an 298 appropriate surrogate matrix, assay sensitivity and linearity was determined using a 299 surrogate-analyte approach. Reverse calibration curves were generated in whole human 300 blood through dilution of deuterium labelled analogues of each analyte in whole blood prior 301 to volumetric spotting on DBS collection cards. The concentration range of each analyte was 302 selected to span a diagnostically relevant concentration range for all three metabolites based 303 on commonly utilized plasma reference ranges [1, 14] . During DBS extraction, samples were 304 spiked with light certified reference standards (fortifying the sample to 1 ng/mL for all three 305 analytes), which were used to normalize the signal for the surrogate analytes. Assay linearity, precision, and accuracy criteria were met for MN (R 2 = 0.9987) (Figure 2A) , NMN 307 (R 2 = 0.9976) (Figure 2B) , and 3MT (Figure 2C) , within the defined concentration range of 308 40 -2000 pg/mL. At all calibration levels, precision was within 15% deviation of the actual 309 concentration with a mean absolute deviation of 6.9%, 7.2%, and 9.5% at the LLOQ for MN, 310 NMN, and 3MT respectively (Table 3) . Because the endogenous concentration of 3MT is 311 typically 5 to 10-fold lower than MN/NMN, and because typical clinical-cutoffs 312 recommended for 3MT to be used as a diagnostic criterion are below the validated limit of 313 quantitation for our DBS assay (typically below 20 pg/mL) [15, 16] , further evaluation of the 314 method in a larger cohort would be needed to determine the efficacy of our method of 315 PCC/PPGL screening. Interestingly, the assay may still provide sufficient analytical 316 sensitivity to measure 3MT in the context of neuroblastoma diagnosis, where it has been 317 demonstrated to serve as a highly sensitive and accurate biomarker [17] [18] [19] [20] . In such cases, 318

3MT concentrations in plasma have been found to be as high as 255 pg/mL, with typical 319 concentrations of approximately 100 pg/mL, compared to 2 to 9 pg/mL in healthy 320 controls [17] . As such, this assay may prove useful for neuroblastoma diagnosis. acquired as reverse calibration curves with increasing IS levels normalized to a constant 324 level of unlabelled reference standards (2 ng mL -1 ). 325 

Assay precision and accuracy were determined by quantifying MNs in independently-330 prepared QC quadruplicates at the LLOQ, 3 x LLOQ, mid-point of the calibration curve, and 331 at 75% of the highest point of the calibration curve (Table 4 ). Our criteria for analytical 332 validation were that the accuracy must be 100% ± 15% and the CVs must be below 15%. 333

The experimental precisions in % CV were 1.8%-3.4%, 3.9-9.3%, and 1.7-10.4% for MN, 334 NMN, and 3MT, respectively. Assay accuracies were 93.0-105.5%, 98.2-103.8%, and 97.9-335 109.4% for MN, NMN, and 3MT, respectively. All of the QC samples passed our validation 336 criteria, with the exception of one of the four QC samples at the LLOQ of 3MT, which 337 deviated by more than 15% from the nominal concentration. Since the remaining three QC 338 samples showed acceptable accuracies and low % CVs, we believe that the failure of this single QC-sample is likely attributable to a technical problem during injection. It was, 340 therefore, excluded from the data analysis. Based on these results, all measurements met the 341 validation criteria, and demonstrated excellent reproducibility and accuracy. 342 343 

In order to assess the stability of MNs from DBS samples under different storage conditions, 350 we fortified whole blood using an equal mixture of MNs reference standards to a final 351 concentration of 500 pg/mL. DBSs were prepared as described above and stored at either 352 room temperature out of direct sunlight, at 4°C, or frozen at -20°C. DBS samples were 353 extracted on the following day, and 6, 9, 15, and 17 days after spotting (Figure 3) All samples were stored with sorbent packets in ZipLoc bags. 374 Figure 6) . The integrated area ratio of the blank to that of 382 the LLOQ must be below 20% for there to be acceptably low levels of carryover between 383 samples. This analysis was done in triplicate, and, for MN, NMN, and 3MT, the average 384 ratios of the blank signals to the LLOQ peak areas were 3.9%, 12.2%, and 3.5%, 385 respectively, indicating that our assay satisfied the requirements for validation. 386

In conclusion, we have demonstrated that on-spot PITC-derivatization LC-MRM is a 388 sensitive, robust, and cost-effective method for the quantification of MN and NMN from a 389 single DBS. This work, therefore, provides a novel diagnostic assay for PPGLs, which 390 facilitates the use of supine sampling as recommended. It alleviates patient discomfort at test centres, which can contribute to falsely elevated levels of metanephrines. Furthermore, 392 because the preparation and storage of DBSs could be done remotely and without causing 393 great patient discomfort and inconvenience, this would facilitate repeated follow-up 394 determination of MN concentrations by DBS sampling over a period of several days. 395

Together, this could result in improvements to diagnostic sensitivity and accuracy, thereby 396 reducing the number of false-positives. This method, therefore, might also reduce the need 397 for follow-up urine/plasma metanephrines, CT-scan, and other confirmatory diagnostic 398 procedures, which are costly, time-consuming, and inconvenient for patients. From our 399 established assay, measurement of 3MT is unlikely to be sensitive enough for application 400 toward the diagnosis of PPGLs from a single DBS due to the intrinsically low concentration 401 of this metabolite, and the relatively modest increase which is of diagnostic utility (<15 402 pg/mL) [15] . Itis possible that by combining multiple DBS samples our validation criteria for 403 sensitivity could be met for this analyte in the context of PPGL diagnosis. In contrast, levels 404 of 3MT are expected to be greatly elevated in pediatric patients with neuroblastomas. 405

Reported concentrations for these patients are sometimes higher than 1000 pg/mL and 406 usually around 100 pg/mL in plasma [15, 17, 20] . This new assay would therefore provide a 407 major advantage over other measurements of 3MT, since DBS sampling is already well 408 established for newborn screening because of the need for sampling of very low amounts of 409 blood with minimal invasiveness. 410 

The study was also supported by the MegaGrant of 418 the Ministry of Science and Higher Education of the Russian Federation

Reference intervals for LC-MS/MS 428 measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated 429 normetanephrine, metanephrine and methoxytyramine

Stability of Plasma Free

Metanephrines during Collection and Storage as Assessed by an Optimized HPLC 437 Method with Electrochemical Detection

Short-term stability of free 440 metanephrines in plasma and whole blood

Isotope-443 labeling derivatization with 3-nitrophenylhydrazine for LC/multiple-reaction 444 monitoring-mass-spectrometry-based quantitation of carnitines in dried blood spots

Multiple Reaction Monitoring

Enables Precise Quantification of 97 Proteins in Dried Blood Spots

Quantitation of 25-hydroxyvitamin D in dried blood spots by 2D LC-MS/MS without 451 derivatization and correlation with serum in adult and pediatric studies

Development and 454 validation of a dried blood spot LC-MS/MS assay to quantify ranitidine in paediatric 455 samples

Short-Term Stabilities 458 of 21 Amino Acids in Dried Blood Spots

State of the Science in Dried Blood Spots

A sensitive, high-throughput LC-MS/MS method 464 for measuring catecholamines in low volume serum

Skyline 467 performs as well as vendor software in the quantitative analysis of serum

Laboratory evaluation of pheochromocytoma and 473 paraganglioma

Plasma methoxytyramine: clinical utility 478 with metanephrines for diagnosis of pheochromocytoma and paraganglioma

Analysis of plasma 3-methoxytyramine, normetanephrine and 482 metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: 483 Utility for diagnosis of dopamineproducing metastatic phaeochromocytoma

Plasma free metanephrines for diagnosis of neuroblastoma patients

3-Methoxytyramine: An independent prognostic biomarker that 492 associates with high-risk disease and poor clinical outcome in neuroblastoma patients

Clinical validation of urine 3-495 methoxytyramine as a biomarker of neuroblastoma and comparison with other 496 catecholamine-related biomarkers

Biochemical testing for 500 neuroblastoma using plasma free 3-O-methyldopa, 3-methoxytyramine, and 501 normetanephrine

Richard designed the experiments with insights from

Richard performed the analytical work and data analysis

Borchers wrote the manuscript

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.X The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:CHB is the CSO of MRM Proteomics, Inc. and the CTO of Molecular You. The other authors declare no conflicts of interest.